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Formoterol is a selective long-acting b2-adrenergic receptor agonist (LABA) that provides
significant and sustained bronchodilatory effect for up to 12 h following a single dose. The
onset of effect is significantly faster with formoterol compared with an alternative LABA,
salmeterol, although both have a similar duration of action. The overall efficacy of
formoterol in improving lung function and controlling symptoms of chronic obstructive
pulmonary disease (COPD) is comparable to that of salmeterol and potentially superior to
that of ipratropium or theophylline. Formoterol provides additional benefit when
administered in combination with other bronchodilators or inhaled corticosteroids. In
clinical studies, formoterol was well tolerated and had an adverse-event profile similar to
that of other b2-adrenergic receptor agonists. Formoterol is a rapidly acting, well-
tolerated, effective b2-adrenergic receptor agonist that can be regularly used as a long-
acting bronchodilator for patients with moderate to severe COPD, as per recommendations
of the current treatment guidelines.
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Chronic obstructive pulmonary disease (COPD) is a preven-
table and treatable disease characterized by airflow limita-
tion that is not fully reversible and accompanied by
pathologic changes in the lung. The airflow limitation,
which is characteristic of COPD, results from a combination
of small airway disease (obstructive bronchiolitis) and
parenchymal destruction (emphysema) secondary to inflam-
mation.1 Although cigarette smoking is the most common
COPD risk factor, air pollution, history of childhood
respiratory illness, exposure to secondhand smoke, occupa-
tional exposure to chemicals, dust, and heredity have also
been implicated.2
More than 122,000 Americans died from this disease in
2003, making COPD both the nation’s fourth leading cause of
death3 and one of the few major diseases associated with
rising mortality rates.4 In the United States, an estimated 16
million adults are diagnosed with the disease and an
additional 14 million may have undiagnosed COPD.4 In 2004,
11.4 million US adults were estimated to have COPD, which
accounted for $37.2 billion in total healthcare expenditures;
$20.9 billion were attributable to direct medical costs.4
The pathology of COPD is generally progressive.1 Char-
acteristic physiologic changes include mucus hypersecre-
tion, ciliary dysfunction, chronic airflow limitation,
pulmonary hyperinflation, gas exchange abnormalities,
pulmonary hypertension, and cor pulmonale.1 Spirometry
provides the most reliable quantitative assessment of airway
function and is an essential tool in the diagnosis, monitoring,
and management of COPD. Forced expiratory volume in 1 s
(FEV1) and forced vital capacity (FVC) are key spirometric
indices. A decrease in the FEV1/FVC ratio often signals the
development of increasing airflow limitation.
Pharmacologic agents that are currently approved for the
treatment of COPD do not modify the progressive decline inlung function, a hallmark of COPD.5 Moreover, airflow
limitation in patients with COPD is only partially reversible.
Therefore, the goal of pharmacotherapy is to treat the
reversible components of COPD and improve patient-
centered outcomes such as symptoms, use of rescue
bronchodilator, and quality of life as measured by St.
Georges Respiratory Questionnaire (SGRQ).1 Thus antic-
holinergics, b2-adrenergic receptor agonists, and methyl-
xanthine-type bronchodilators have a critical role in
management of the disease. Inhaled agents are generally
preferred over systemic agents because of their lower
potential for adverse events. Treatment regimens vary with
disease severity. As-needed use of a short-acting broncho-
dilator may be sufficient for patients with mild disease
(Stage I), whereas regularly scheduled treatment with a
long-acting bronchodilator or a combination may be
necessary in moderate to severe disease (Stages II–IV).1
Formoterol and salmeterol are two inhaled long-acting b2-
adrenergic receptor agonists (LABAs). Formoterol is avail-
able in a capsule dosage form containing a dry-powder
formulation for oral inhalation and is approved for long-
term, twice-daily maintenance treatment of bronchocon-
striction in patients with COPD.6 Consistent with its drug
class effects, formoterol stimulates b2-adrenergic receptors
in the airways, inducing airway smooth muscle relaxation
and reducing or preventing bronchoconstriction.7 Affinity of
formoterol is highly selective for the b2-receptor with
minimal affinity for b1- and a-adrenergic receptors.
7,8
There are two important differences between formoterol
and salmeterol. The first difference is the relative degree of
b2-receptor activation. Results from methacholine-chal-
lenge studies have shown that formoterol elicits a dose-
dependent protective response, whereas salmeterol is
associated with both a flatter dose–response curve and
significantly weaker protection against bronchoconstriction.
These results suggest that salmeterol exerts partial
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selective b2-agonist.
9–11 The greater peak bronchodilatory
effect with formoterol compared with salmeterol9 appears
consistent with this finding. The second difference between
the two LABAs is that the onset of action with formoterol is
significantly faster than with salmeterol.12 This review
summarizes the key findings from several clinical studies
that investigated the clinical topics related to use of
formoterol in patients with COPD.
Onset of action and duration of effect with
formoterol
Thirteen crossover trials have evaluated the effects of
formoterol in patients meeting the diagnostic criteria for
moderate to severe COPD (Table 1).12–24 All but three of
these trials included a placebo arm and all but one included
an active comparator arm. The results of these studies
strongly support the conclusion that the onset of action with
formoterol is faster than that with anticholinergic agents or
salmeterol and similar to that of short-acting b2-adrenergic
receptor agonists (SABAs), such as albuterol. These studies
also confirm that the duration of action of both formoterol
and salmeterol (X12 h) is consistent with the twice-daily
dosing schedule approved for these agents.
Formoterol versus placebo
The only study in the series that did not incorporate
an active comparator was conducted by Maesen and
coworkers13 in 12 patients with poorly reversible COPD
(FEV1 increase o9% predicted following inhalation of 1mg
terbutaline) of at least moderate severity (FEV1 30–60%
predicted). In this early pilot study, once-daily formoterol 6
or 24 mg produced modest, but rapid increases in FEV1 within
10min of administration. The mean increases in FEV1 were
below the threshold of reversibility (3.4% and 6.8% with
formoterol 6 and 24 mg, respectively). However formoterol
24 mg produced greater increase in FEV1 than formoterol 6 mg
or placebo (P ¼ 0.002). Maximum increase in FEV1 of 7.4%
and 10.0% was achieved 2 h after administration of
formoterol 6 and 24 mg, respectively, versus 3.6% with
placebo. The mean increase in FEV1 over 12 h was not
statistically different between treatments (formoterol 6 mg
(0.12 L), 24 mg (0.23 L), and placebo (0.05 L)). However,
formoterol 6 and 24 mg significantly reduced the mean work
of breathing (P ¼ 0.0007) and airway resistance (P ¼ 0.003)
10min post-treatment and significantly reduced the 12-h
area under the curve (AUC012 h) values for work of breath-
ing (P ¼ 0.03) versus placebo. The authors concluded that
formoterol is effective in the management of COPD even in
patients with poorly reversible airway obstruction.
Formoterol versus salmeterol
The effects of single-dose formoterol and salmeterol were
examined in three crossover studies and one subset
analyses.14 The results from all of these studies demon-
strated that the onset of bronchodilation with formoterol
was faster than salmeterol. The largest (n ¼ 47) and mostrecent of these studies was a multicenter trial conducted
by Kottakis and associates.14 Patients received formoterol
(12 and 24 mg) or salmeterol (50 and 100 mg). The FEV1 AUC
during the first hour post-treatment (AUC0–1 h) and the
percentage change from baseline in FEV1 were greater with
formoterol 12 mg than salmeterol 50 mg (P ¼ 0.0044 and
0.0021, respectively). Similarly, formoterol 24 mg induced
greater improvement than salmeterol 100 mg (P ¼ 0.0001
and 0.0001, respectively). Formoterol 24 mg, but not
formoterol 12 mg, produced a greater peak bronchodilatory
effect than salmeterol 50 mg (P ¼ 0.0004). Both doses of
formoterol resulted in a more rapid onset of action than the
corresponding doses of salmeterol and placebo. The median
time to a 15% increase in FEV1 above maximum predose level
was 5min with both doses of formoterol compared with 15
and 10min with salmeterol 50 and 100 mg, respectively. A
15% increase in FEV1 above maximum predose level within
5min of dosing was achieved by approximately three times
as many patients receiving formoterol as those receiving
salmeterol. The authors concluded that formoterol 12 and
24 mg provided a faster onset of bronchodilation than the
corresponding doses of salmeterol.
Bouros and coworkers12 performed a post hoc analysis of
lung function data from the above study, to evaluate the
mean change in inspiratory capacity (IC) with formoterol
12 mg versus salmeterol 50 mg. The result showed that
treatment with formoterol 12 mg led to a greater improve-
ment in IC values at 5 and 10min post-treatment than
salmeterol 50 mg (P ¼ 0.0024 and 0.0033, respectively).
Between-treatment differences persisted throughout the
first 60min post-treatment. Formoterol 24 mg also provided
a greater improvement in IC (AUC0–1 h) than salmeterol
100 mg (P ¼ 0.0043).
Similarly, Celik and coworkers15 showed that treatment
with formoterol 12 mg resulted in a faster onset of action
than salmeterol 50 mg. The baseline spirometric values for
formoterol, salmeterol, and placebo groups were compar-
able. The mean increase from baseline in FEV1 10min post-
treatment was significantly greater with formoterol (0.2 L;
18%) than with placebo (0.04 L; 3.9%; Po0.05) and
salmeterol (0.11 L; 9%). Twenty min post-treatment, the
mean increase from baseline in FEV1 was significantly
greater with both formoterol and salmeterol than placebo.
The mean peak bronchodilation occurred faster with
formoterol (60min) than salmeterol (120min); however,
increases in FEV1 throughout the 12-h monitoring period was
similar with both drugs and significantly greater than
placebo (Po0.05).
Cazzola and colleagues25 compared the effects of once-
daily formoterol (12, 24, or 36mg) or salmeterol (25, 50, or
75mg) administered on nonconsecutive days to patients with
severe COPD. Peak bronchodilation (mean maximum increase
in FEV1) occurred 1h earlier with all three doses of formoterol
than the corresponding doses of salmeterol. Both agents
consistently improved spirometry indices over the 12-h
monitoring period (Po0.01, both drugs versus placebo);
however, the mean FEV1 AUC was greater with salmeterol
50mg compared with formoterol 12 and 24mg, but not with
formoterol 36mg. Formoterol was associated with a dose-
dependent increase in FEV1, FVC, and forced expiratory flow
at 50% of FVC (FEF50). In contrast, salmeterol 75mg provided
no additional benefit over salmeterol 50mg.
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Table 1 Studies of formoterol onset of action and duration of effect.
Author N Mean age
(yr)
Study drugs Design Key findings
Benhamou et al.,18 24 61.6 Single-dose: FORM
24 mg; ALB 400 mg
R, DB, PC,
3-way xvr
Drugs similar to each other,
significantly different from placebo
in 0–30min post-treatment increase
in FEV1 AUC versus baseline
Bouros et al.,12 47 63.5 Single-dose: FORM
12 mg; FORM 24mg;
SAL 50mg; SAL 100 mg
R, DB, PC, DD,
MC, 5-way xvr
FORM 12 and 24mg produced
statistically greater increase in IC
than both SAL 50 and 100 mg at all
time points during first 60min post-
treatment (Pp0.0431)
Cazzola et al.,21 20 70.7 Single-dose: FORM
12 mg; TIO 18mg;
FORM 12mg+TIO 18 mg
R, DB, DD,
3-way xvr
FORM, FORM/TIO showed
significantly faster onset, trends to
greater FEV1 improvement versus
TIO alone. TIO, FORM/TIO
associated with greater FEV1 24 h
post-treatment versus baseline
(P ¼ 0.003 and 0.045, resp.) FORM
versus baseline (NS)
Cazzola et al.,16 20y 60.6 Group A Single-dose:
FORM 9 mg; ALB
100 mg Group B Single
dose: FORM 18 mg;
ALB 200 mg
R, DB,DD,
2-way xvr
Onset of effect with FORM similar to
that with ALB as measured by FEV1 5
and 15min post-treatment
Cazzola et al.,17 16 65.6 Single-dose: FORM
12 mg; FORM 24mg;
ALB 400 mg; ALB
800 mg
R, DB,PC DD,
5-way xvr
No significant between-treatment
differences in time to X15%
increase in FEV1 versus baseline or
time to X200mL absolute increase
in FEV1 versus baseline
Cazzola et al.,19 16 64.3 Single-dose: FORM
24 mg; SAL 50 mg; ALB
200 mg
R, SB, PC,
4-way xvr
ALB onset faster than FORM or SAL
as determined by time to X 15%
FEV1 increase versus baseline (both
Po0.05). FORM onset more rapid
than SAL in 9/16 patients, overall
mean values NS
Celik et al.,15 22 57.3 Single-dose: FORM
12 mg; SAL 50 mg
R, DB, PC,
3-way xvr
Significant increase in FEV1 10min
post-treatment with FORM
(200mL), not SAL (40mL),
versus PB and baseline. FORM,
SAL effects on FEV1 (250mL and
200mL, resp.) significantly
different from PB, baseline 20min
post-treatment. FORM, SAL peak
effects attained at 60 and 120min
resp. Both drugs superior to PB 12 h
post-treatment
Chhabra et al.,23 44 56.2 Single-dose: FORM
12 mg; IPRA 40mg
R, DB, PC,
3-way xvr
FEV1 change over baseline 5min
post-treatment greater with FORM
compared with IPRA (Po0.01).
Effects equivalent 30min post-
treatment. Overall absolute
increase in FEV1, FVC with FORM
and IPRA similar
W.E. Berger, J.A. Nadel176
ARTICLE IN PRESS
Table 1 (continued )
Author N Mean age
(yr)
Study drugs Design Key findings
Di Marco et al.,22 20 65 Single-dose: FORM
12mg; SAL 50mg; ALB
200 mg; OXIT 200 mg
R, DB, PC,
5-way xvr
All active therapies associated with
improvements in FEV1 and IC versus
baseline (all Po0.05). FORM effects
on FEV1 superior to SAL at 30min
(P ¼ 0.01), all b-agonists superior
to OXIT at 30, 60, 120min.FORM
effects on IC superior to SAL at
30min, superior to OXIT at 15,
30min
Kottakis et al.,14 47 63.5 Single-dose:FORM
12mg; FORM 24 mg;
SAL 50mg; SAL 100 mg
R, DB, PC, DD,
MC, 5-way xvr
FORM 12 and 24mg superior to
corresponding SAL 50 and 100 mg
doses on primary endpoint of FEV1
AUC0–1 h. FORM 24 mg produced
highest mean peak FEV1 (1.63L),
followed by FORM 12mg (1.58 L).
FORM superior to SAL for all pair
contrasts of FVC mean treatment
differences in AUC0–1 h
Maesen et al.,13 12z 61 Single-dose: FORM
6mg; FORM 24 mg
R, DB, PC,
3-way xvr
Compared with placebo, FORM
(both doses) produced statistically,
clinically relevant improvement in
work of breathing and airway
resistance within 10min post-
treatment and persisting 12 h post-
treatment. FEV1 improvement
limited
Richter et al.,24 38 64 Multiple-dose: FORM
12mg, BID x 7 d; TIO
18mg QD x 7 d
R, OL, MC,
2-way xvr
Primary endpoint of FEV
AUC10–120min greater with FORM
versus TIO. Between-treatment
difference in per protocol
population 124mL after first dose
(day 1) (P ¼ 0.016), 80mL after last
dose (day 7) (P ¼ 0.036). FEV1 AUC
0–12 h similar with both drugs
Sichleditis et al.,20 27 64.7 Single-dose: FORM
12mg; FORM 24 mg;
IPRA 40 mg; IPRA
80mg; FORM
12mg+IPRA 40mg
R, SB, PC,
6-way xvr
Combination produced significantly
greater FEV1 improvement versus
IPRA 40 and 80mg (both Po0.05),
but not FORM 12 or 24mg (NS). Mean
peak change in FEV1 with all drugs/
doses significantly greater versus
placebo
ALB ¼ albuterol; DB ¼ double-blind; AUC ¼ area under the curve; DD ¼ double-dummy; FEV1 ¼ forced expiratory volume at 1 second;
FORM ¼ formoterol; FVC ¼ forced vital capacity; IPRA ¼ ipratropium; MC ¼ multicenter; NS ¼ non significant; OL ¼ open-label;
OXIT ¼oxitropium; PC ¼ placebo-controlled; QD ¼ once-daily; R ¼ randomized; SAL ¼ salmeterol; SB ¼ single-blind; TIO ¼ tiotropium;
xvr ¼ crossover.
Single-blind with albuterol.
yPopulation also included patients with intrinsic asthma.
z‘‘Poorly reversible’’ COPD patients as defined by o9% of predicted FEV1 increase following inhalation of terbutaline 1mg.
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Albuterol has a very rapid onset of effect, which makes it
particularly useful as a rescue medication in patients with
COPD or asthma who experience symptom exacerbations.Formoterol, demonstrated to have a rapid onset of action,
was compared with albuterol in three small crossover studies
as both a rescue and maintenance medication in patients with
COPD.16–18 The results of these studies suggest that formoter-
ol has a rapid onset of action similar to albuterol.
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of formoterol 24 mg with albuterol 400 mg. The mean
increase in FEV1 AUC0–30min (the primary efficacy variable)
was similar between formoterol (5.89 L/min) and albuterol
(6.06 L/min), but significantly greater than placebo
(–0.32 L/min; both Po0.0001). Improvement in FEV1 from
5min to 3 h post-treatment was also similar with formoterol
and albuterol. Both drugs induced almost maximal bronch-
odilation by 30min post-treatment, with 80% of maximal
effect occurring within 5min.
Cazzola and coworkers16,17 also compared the onset of
action of formoterol with albuterol in two crossover trials.
One study compared once-daily formoterol (9 and 18 mg)
with once-daily albuterol (100 and 200 mg) in 20 patients
with intrinsic asthma or COPD.16 Improvement in FEV1 at 5-
and 15-min intervals after inhalation of formoterol 9 and
18 mg was similar to albuterol 100 and 200 mg (P ¼ 0.704 and
0.260, respectively). The mean time to response, defined as
a 15% increase in FEV1 above baseline, ranged from 5min
with albuterol 200 mg to 17.5min with formoterol 9 mg. The
onset of action of both agents was similar when the
bronchodilating effect in responders was expressed either
as a percentage of maximum response attained within 5min
post-treatment or as the time required for achieving a 15%
increase in FEV1 versus baseline. The authors concluded that
formoterol is a useful alternative to SABAs for as-needed
use. The other study compared formoterol 12 and 24 mg with
albuterol 400 and 800 mg, which are higher than normal
clinical doses of albuterol.17 The mean time required to
achieve a 15% increase in FEV1 over baseline was 15.2 and
15.1min with formoterol 12 and 24 mg, respectively, and
13.6 and 14.5min with albuterol 400 and 800 mg, respec-
tively. The mean time to increase in FEV1X200mL was also
similar between the two treatments.
Formoterol versus salmeterol and albuterol
Cazzola and associates19 compared the onset of action of
formoterol 24 mg, salmeterol 50 mg, and albuterol 200 mg in a
small (n ¼ 16) study population. The mean time to 15%
increase in FEV1 from baseline was shorter with albuterol
(4min) compared with formoterol (11min) and salmeterol
(10min) (Po0.05). Time to maximum increase in FEV1 with
albuterol, formoterol, and salmeterol was 1, 4, and 5 h,
respectively. These results differ markedly from results
reported later by this same group 16,17 and by Benhamou and
colleagues.18
Formoterol versus ipratropium
Two crossover studies demonstrated that formoterol has a
faster onset of effect than the short-acting anticholinergic
bronchodilator, ipratropium. Sichletidis and colleagues20
evaluated the bronchodilatory effects of formoterol 12 and
24 mg, ipratropium 40 and 80 mg, and a combination of
formoterol 12 mg with ipratropium 40 mg in 27 patients who
were receiving a SABA, ipratropium, and an inhaled
corticosteroid (ICS) at entry into the study. The mean
increase in peak FEV1 with formoterol 12 mg and ipratropium
40 mg combination was greater than that with either dose of
ipratropium (40 mg, P ¼ 0.0025 or 80 mg, P ¼ 0.01) alone,but not formoterol alone (P ¼ NS for both 12 and 24 mg). A
mean increase of 15% in FEV1 from baseline occurred at
10min after both doses of formoterol, 15min after
combination therapy, and at 30 and 60min after ipratropium
40 and 80 mg, respectively. The mean FEV1 AUC0–6 h,
AUC6–12 h, and AUC0–12 h values with combination therapy
were significantly greater than those with ipratropium 40 mg
(P ¼ 0.0023, Po0.0005, and Po0.0005, respectively) and
80 mg (P ¼ 0.003, Po0.0005, and P ¼ 0.0003, respectively),
but not formoterol. These results suggest that addition of
ipratropium to formoterol does not result in additional
benefit in patients with stable COPD.
Chhabra and coworkers23 compared the onset of action of
formoterol 12 mg with ipratropium 40 mg. Formoterol elicited
a greater improvement in FEV1 within 5min post-treatment
compared with ipratropium (18.1% versus 13.9%, respec-
tively; Po0.01). Other indices of lung function, including
FVC, functional residual capacity, residual volume, slow
vital capacity, and total lung capacity, assessed at 5, 30, and
60min post-treatment were similar between active drugs
and significantly different from placebo. The authors
concluded that formoterol is associated with a faster onset
of action than ipratropium; however, both agents were
equally effective in improving lung function.Formoterol versus tiotropium
Two studies compared formoterol with the long-acting
anticholinergic bronchodilator tiotropium.21,24 Similar to
the results of the comparison with ipratropium, formoterol
has a faster onset of action than tiotropium.
Richter and coworkers24 compared treatment with for-
moterol 12 mg twice-daily (BID) and tiotropium 18 mg once
daily (QD) over 7 days in 38 patients. Data obtained after the
first and last doses demonstrated that treatment with
formoterol resulted in a greater FEV1 AUC10–120min at both
time points compared with tiotropium (P ¼ 0.016 and 0.036,
respectively). In the per-protocol study population (n ¼ 34),
the between-treatment difference was 0.124 L after the
first dose and 0.08 L after 7 days of treatment in favor of
formoterol. Between-treatment differences in mean FEV1
AUC0–720min values, use of rescue medication, and other
secondary outcomes were not significant.
Cazzola and coworkers21 studied formoterol 12 mg and
tiotropium 18 mg alone and in combination in a small
(n ¼ 20) trial. At 10min post-treatment, the mean change
in FEV1 with formoterol/tiotropium combination was greater
than with tiotropium alone (0.085 versus 0.039 L, respec-
tively; P ¼ 0.016) but not greater than with formoterol
alone (0.085 versus 0.088 L, respectively; P ¼ NS). Similarly,
the mean maximal increase in FEV1 with combination
therapy (0.21 L) exceeded that with tiotropium alone
(0.18 L) more than that with formoterol alone (0.19 L). The
mean increases in FEV1 AUC0–12 h and AUC0–24 h showed only
nonsignificant trends favoring the combination. In all three
treatment arms, mean FEV1 values were significantly higher
than baseline levels at 12 and 24 h post-treatment. The two
agents were considered complementary in that formoterol
provided faster onset of action and greater maximal
response, whereas tiotropium provided a longer duration
of action.
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oxitropium
Di Marco and coworkers22 assessed treatment with single
doses of formoterol 12 mg, albuterol 200 mg, salmeterol
50 mg, and oxitropium 200 mg in 20 patients with COPD.
Increase in FEV1 at 5min post-treatment was observed in all
active treatment groups. Treatment with formoterol and
albuterol resulted in increased IC levels at 5min whereas
treatment with salmeterol and oxitropium resulted in IC
levels at 15 and 30min, respectively. Among patients with
reduced IC at baseline, significantly greater improvements
in IC were observed only in patients receiving formoterol.
Increases in FEV1 at 5 and 15min after treatment with
formoterol were comparable to those with albuterol and
greater than those achieved with salmeterol. Improvements
in FEV1 30min post-treatment were also greater with
formoterol than salmeterol (P ¼ 0.01). At 30, 60, and
120min post-treatment, increases in FEV1 with formoterol,
albuterol, and salmeterol exceeded those with oxitropium.
Maximum increases in IC and FEV1 were attained 30min
after inhalation of each bronchodilator, with no additional
improvement at either 60 or 120min. The authors concluded
that at standard dosages, formoterol elicited a greater
average increase in IC than salmeterol or oxitropium.
Efficacy of formoterol in randomized controlled
trials
Four large, placebo-controlled clinical trials evaluated the
efficacy of treatment with formoterol for up to 12 months in
patients with COPD (Table 2).26–29 Outcome variables
included spirometric indices, use of rescue medication,
and other measures of symptom control. Three of the four
trials included an active comparator. Overall findings
demonstrate that the efficacy with formoterol is sustained
over periods of up to 12 months of continuous use and is
comparable, and in some instances superior, to that
associated with other bronchodilators.
Improvement in lung function with formoterol
A 12-week dose-ranging study (n ¼ 692) conducted by
Aalbers and coworkers26 demonstrated that twice-daily
treatment with formoterol 4.5, 9, and 18 mg resulted in
increased FEV1 levels compared with placebo (P ¼ 0.010,
0.039 and 0.001, respectively). Although a graded dose-
dependent response was evident in the FEV1 data, a
confirmatory statistical analysis of the data was not
conducted.
Similar improvements in lung function were reported by
Dahl and colleagues27 in a 3-month study (n ¼ 780) of
formoterol 12 or 24 mg BID and ipratropium 40 mg four times
daily (QID). Treatment with either dose of formoterol
resulted in greater mean FEV1 AUC0–12 h values than
treatment with ipratropium (both Pp0.024) or placebo
(both Po0.001). Furthermore, increase in FEV1 with either
dose of formoterol was clinically relevant (i.e.X0.120 L) at
all post-treatment time points from 5min through 12 h on
both the first and last study days. Treatment with either
dose of formoterol also resulted in superior improvement inFEV1 over the first 6 h post-treatment compared with
ipratropium. The authors concluded that formoterol was
more effective than ipratropium for the treatment of
patients with COPD.
Campbell and associates29 evaluated the suitability of
formoterol for both maintenance and as-needed (rescue)
therapy. Patients (n ¼ 657) with an FEV1 40–70% predicted
received formoterol 9 mg BID plus formoterol 4.5mg as-
needed (PRN) (Group A), formoterol 9mg BID plus terbuta-
line 0.5mg prn (Group B), or placebo plus terbutaline 0.5mg
PRN (Group C) for a period of 6 months. Patients receiving
formoterol achieved greater increase in mean FEV1 0.5–2 h
post-treatment (5.0% Group A, 10.2% Group B) than patients
in Group C (1.4%; Po0.01 versus placebo). Patients
receiving formoterol also achieved greater morning peak
expiratory flow (PEF) rates compared with patients in Group
C (Group A ¼ 17%; Group B ¼ 23%; Group C ¼ 2%; Po0.001
both comparisons).
Rossi and colleagues28 extended these findings by showing
that formoterol 12 or 24 mg BID maintained improvement in
lung function over 12 months in a population of 854 patients.
Both doses of formoterol were superior to placebo, as
assessed by FEV1 AUC0–12 h values at 3 and 12 months. The
differences in FEV1 AUC values in the formoterol treatment
arms were 40.120 L at all time points and statistically
significantly higher than those in the placebo group
(Po0.001). Furthermore, improvements in PEF rates were
significantly greater at all time points in patients receiving
formoterol than in patients receiving placebo (Po0.001).Improvement in symptoms and the need for rescue
medication with formoterol
The formoterol efficacy studies described previously as-
sessed symptom control and reduction in the use of rescue
medication.26–29 Formoterol treatment was associated with
overall consistent and favorable results. Aalbers and cow-
orkers26 observed that doses of formoterol as low as 4.5 mg
BID improved symptom scores for breathlessness, cough,
chest tightness, and sleep disturbance. Total symptom
scores improved by 6% and 8%, with formoterol 4.5 and
9 mg BID (P ¼ NS), respectively, and by 13% with formoterol
18 mg BID (P ¼ 0.002). Treatment with formoterol 9 and
18 mg also resulted in more symptom-free days (11.3% and
12.3%, respectively) than treatment with placebo (6.6%;
Pp0.025, both comparisons).
Dahl and coworkers27 corroborated these findings by
demonstrating that formoterol 12 and 24 mg BID were
superior to placebo in lowering total symptom scores
(perform usual daily activity, breathlessness on rising and
over each 24-h period, waking at night due to respiratory
symptoms, cough, and sputum production) (Po0.001 and
P ¼ 0.007, respectively). Treatment with either dose of
formoterol also resulted in a significant reduction in the use
of rescue medication (Po0.001 versus placebo).
Similarly, Campbell and associates29 found that total
scores for COPD-related symptoms improved with formoter-
ol 9 mg BID compared with placebo (Po0.05). Treatment
with formoterol also resulted in a reduction in the use of
rescue medication during the day and at night and an
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Table 2 Controlled Studies of Formoterol With/Without an Active Comparator.
Author N Mean age
(yr)
Study drugs Study design/
duration
Key findings
Aalbers et al.,26 692 62.4 FORM 4.5 mg, 9 mg,
18 mg BID
R, DB, PC, PG,
MC/12wk
FORM improved lung function at all
doses. FORM 9, 18mg reduced
selected symptom scores, relief
medication use, increased
symptom-free days. Only 18mg dose
associated with significantly
improved TSS, TDI
Dahl et al.,27 780 63.7 FORM 12mg, 24mg
BID; IPRA 40mg QID
R, DB, PC, PG,
MC/12wk
Both FORM 12, 24 mg superior to
IPRA in terms of FEV1 AUC 0–12 h
primary efficacy variable as well as
rescue medication use. FORM 12mg,
but not 24 mg, superior to IPRA in
reducing TSS
Campbell et al.,29 657 60 FORM 9 mg BID+TER
0.5mg prn; FORM
9 mg BID + FORM
4.5 mg prn; P+TER
0.5mg prn
R, DB, PC, PG,
MC/6mo
Both FORM regimens significantly
increased FEV1 values, decreased
CSS, and prn medication use versus
P. FORM 9/4.5 mg provided
significantly better FEV1
improvement versus FORM 9 mg/TER
0.5mg (Po0.05)
Rossi et al.,28 854 63 FORM 12mg, 24mg
BID;THEO 200-300mg
BID
R, DB, PC, PG,
MC/12mo
All active treatments associated
with clinically relevant increases in
FEV1 AUC at months 3 and 12. FORM
12mg superior to THEO at months 3
and 12, FORM 24mg only at month 3.
Median TSS similar among active
drugs
Vervloet et al.,30 482 48 FORM 12mg BID; SAL
50 mg BID
R, OL, PG,
MC/6mo
Active drugs had similar effect on
primary endpoint of mean morning
pre-dose PEF, mean rescue
medication use, RSS. FORM
produced superior improvements in
evening predose PEF at months 2-4
(Po0.05)
AUC ¼ area under the curve; BID ¼ twice-daily; CSS ¼ combined symptom score; FORM ¼ formoterol; IPRA ¼ ipratropium;
MC ¼ multicenter; OL ¼ open-label; P ¼ placebo; PC ¼ placebo-controlled; PEF ¼ peak expiratory flow; PG ¼ parallel group;
QID ¼ four times daily; R ¼ randomized; RSS ¼ respiratory symptom score; SAL ¼ salmeterol; TDI ¼ transitional dyspnea index;
TER ¼ terbutaline; THEO ¼ theophylline; TSS ¼ total symptom score.
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(all Po0.05 versus placebo).
In contrast, Rossi and coworkers28 reported only modest,
nonsignificant improvements in COPD-related symptom
scores with formoterol 12 or 24 mg BID after 12 months of
treatment. However, treatment with either dose of for-
moterol reduced the frequency of mild COPD exacerbations
(Pp0.008) and rescue medication use (Pp0.003) compared
with placebo. Treatment with formoterol 24 mg also resulted
in a reduction in COPD exacerbations of moderate severity
(P ¼ 0.043). Notably, only 4.7% (10/211) of patients receiv-
ing formoterol 12 mg and 2.3% (5/214) of patients receiving
formoterol 24 mg required hospitalization for severe COPDexacerbations compared with 9.1% (20/220) of patients
receiving placebo.
Efficacy of formoterol versus other
bronchodilators
Formoterol versus salmeterol
Vervloet and colleagues30 conducted a 6-month study in 482
patients with COPD regularly using ICSs (Table 2). Patients
received either formoterol 12 mg BID or salmeterol 50 mg BID.
Improvements in morning predose PEF rates, COPD-related
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both groups. Patients receiving formoterol experienced
superior improvements in evening predose PEF rates at
months 2, 3, and 4 (Po0.05 versus salmeterol).
Formoterol versus inhaled anticholinergics
The effectiveness of formoterol monotherapy has been
compared with that of ipratropium or tiotropium mono-
therapy in two trials.27,31
Ipratropium
A 12-week comparison of formoterol (12 or 24 mg BID) and
ipratropium (40 mg QID) by Dahl and coworkers27 demon-
strated that formoterol was superior to ipratropium in
improving lung function and controlling COPD symptoms
(Table 2). Although treatment with either agent resulted in
clinically and statistically (for both treatments Po0.001
versus placebo) significant increases in FEV1 AUC, the
improvements with formoterol were significantly better
than those with ipratropium (Pp0.024). COPD symptoms
improved significantly with formoterol 12 and 24 mg than
placebo (Po0.001 and P ¼ 0.007, respectively). Formoterol
12 mg was also superior to ipratropium in improving COPD
symptoms (P ¼ 0.009). Treatment with either dose of
formoterol resulted in a significant reduction in the use of
rescue medication compared with ipratropium (both Pp
0.014) and placebo (both Po0.001).
Tiotropium
The efficacy of formoterol 12 mg BID and tiotropium 18 mg QD
was compared in an 18-week crossover trial conducted by
van Noord and colleagues (Table 3).31 Treatment with
tiotropium resulted in greater average daytime FEV1 levels
over 12 h than formoterol (Po0.03). The differences in FEV1
levels between the two treatment groups were most
noticeable at 8–12 h after the morning dose of formoterol
(Po0.002), whereas no significant between-treatment
differences in FEV1 occurred following the evening dosing
of formoterol, except for a higher 24-h (trough) FEV1 level
with tiotropium (Po0.05). Patterns of improvements in FVC
were similar to those for FEV1 and favored tiotropium.
Nighttime use of rescue medication was comparable
between the two treatment groups.
Formoterol versus theophylline
Rossi and associates28 compared the efficacy of formoterol
12 or 24 mg BID with that of theophylline in a large-scale
(n ¼ 854), 12-month, placebo-controlled, parallel-group
trial (Table 2). FEV1 AUC0–12 h levels at months 3 and 12
with either dose of formoterol or theophylline were superior
to placebo (Po0.001 and Pp0.007, respectively). Moreover,
treatment with either dose of formoterol was superior to
treatment with theophylline at month 3 (Pp0.016 for both
doses) and treatment with formoterol 12 mg was superior to
theophylline at month 12 (P ¼ 0.026). Whereas morning PEF
improved significantly in all three active treatment arms
(Po0.001 for both doses of formoterol versus placebo,
P ¼ 0.007 for theophylline versus placebo), improvements
were significantly better with either dose of formoterol thantheophylline (all Pp0.020). The mean percentage of days
with mild COPD exacerbations was also lower in both
formoterol arms than in the theophylline arm (both
Pp0.035; P ¼ NS for theophylline versus placebo). The
mean percentage of days with moderate COPD exacerba-
tions was lower in both the formoterol 24 mg arm and
theophylline arm than placebo arm (P ¼ 0.043 and 0.019,
respectively).
Effectiveness of formoterol in combination
therapies
The effects of formoterol combination therapy on lung
function and COPD exacerbations were evaluated in 4
crossover and 2 parallel-group studies (Table 3).31–36 The
results of these studies support the hypothesis that
combination therapy of LABA, such as formoterol with other
bronchodilators such as anticholinergic agents or theophyl-
lines result in additional benefits in patients with COPD. The
current treatment guidelines recommend addition of one or
more long-acting bronchodilators in patients with moderate
to severe COPD.37
Formoterol plus long-acting bronchodilators
Van Noord and colleagues31 compared monotherapy with
formoterol 12 mg BID or tiotropium 18 mg QD with once-daily
combination therapy with these two agents. Morning
administration of formoterol/tiotropium combination re-
sulted in FEV1 values that were higher at each time point
and over 24 h than those with formoterol BID and tiotropium
QD (all Po0.0001). Combination therapy also resulted in
higher morning and evening PEF values versus monotherapy
with either agent (both Po0.02) and reduced daytime, but
not nighttime, use of rescue medication (both Po0.01). The
authors concluded that once-daily combination treatment
with formoterol/tiotropium provided additive and sustained
24-h activity that was superior to that with monotherapy
with either agent.
A second crossover study by the van Noord group33
investigated the effects of adding once-daily or twice-daily
treatment with formoterol 12 mg to standard treatment with
tiotropium 18 mg QD. Addition of formoterol in the morning
resulted in increased AUC0–12 h and AUC0–24 h levels for FEV1,
FVC, and IC compared with tiotropium alone (all Po0.05).
Addition of twice-daily dosing with formoterol resulted in
additional increases in AUC12–24 h levels for FEV1 and FVC
compared with tiotropium alone or formoterol alone once
daily (Po0.05). Combination therapy with once-daily or
twice-daily formoterol also resulted in a significant reduc-
tion in the use of rescue medication during the daytime
versus treatment with tiotropium alone (Po0.01). The
authors concluded that addition of either once-daily or
twice-daily formoterol offered multiple benefits versus
treatment with tiotropium alone
Di Marco and associates34 conducted a pilot crossover
study with formoterol 12 mg and tiotropium 18 mg alone and
in combination in 21 patients with acute exacerbations of
COPD. Unlike the previous trial, patients only received
formoterol once daily. Combined therapy resulted in greater
AUC0–12 h and AUC0–24 h levels for FEV1, FVC and IC than
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Table 3 Studies of Formoterol in Combination Use.
Author N Mean age
(yr)
Study drugs Study design/
duration
Key findings
Calverley et al.,40 1022 a BUD 200 mg BID;
FORM 4.5 mg BID;BUD
160 mg BID + FORM
4.5 mg BID
R, DB, PC, PG,
MC/12mo
Combination superior to BUD and
FORM (Po0.001 and 0.002, resp.) in
maintaining FEV1 achieved during
steroid run-in period. Combination
prolonged time to first exacerbation
versus both comparators (Po0.05),
also reduced reliever medication
use (Po0.001 and Po0.05, BUD and
FORM resp.)
Cazzola et al.,38 16 67.1 FORM 12mg + BUD
400 mg  1; SAL 50 mg
+FLU 250 mg x1
R, SB, 2-way
xvr/4 d
(2 2 d)
FORM/BUD combination effects on
FEV1 greater at 120 and 360min
(both Po0.05). AUC0–12 h and
effects on IC similar between
groups
Celik et al.,35 117b 65.7c IPRA 40mg QID +
FORM 12mg BID; IPRA
40 mg QID +FORM
12 mg BID +MKT 10mg
hs
R, SB,
PG/2mo
Addition of MKT resulted in greater
improvements in FEV1, FVC, PEF
and SGRQ versus non-MKT
combination (all Po0.05). No
significant changes versus baseline
noted in IPRA/FORM combination
group
Di Marco et al.,34 21 72 FORM 12mg BID; TIO
18 mg QD; FORM 12 mg
BID +TIO 18 mg QD
R, DB, DD,
3-way xvr 3 d
(3 1d)
Mean FEV1, FVC, IC AUC0–12 h and
AUC0–24 h greater with FORM/TIO
versus either monotherapy
(Po0.01). Maximum FEV1 greater
with FORM/TIO versus either
monotherapy (Po0.01). FORM
alone superior to TIO alone
(Po0.05)
D’Urzo et al.,32 172 65 IPRA 40mg QID +FORM
12 mg BID; IPRA 40 mg
QID +ALB 200 mg QID
R, DB, DD,
MC, 2-way
xvr/6wk
(3wk 2)
Morning PEF, FEV1 AUC higher with
IPRA/FORM than IPRA/ALB
(P ¼ 0.0003 and Po0.0001, resp).
IPRA/FORM associated with lower
mean TSS (P ¼ 0.0042)
Szafranski et al.,39 812 64 BUD 200 mg BID;
FORM 4.5 mg BID; BUD
160 mg BID +FORM
4.5 mg BID
R, DB, PC, PG,
MC/12mo
BUD/FORM produced greater FEV1
increase than BUD alone
(Po0.001), but not FORM alone.
Fewer severe exacerbations with
combination versus FORM
(Po0.001) but not BUD. Superior
PEF with combination versus BUD,
FORM, P
Van Noord et al.,33 95 64 TIO 18mg QD; TIO
18 mg QD +FORM 12 mg
QD; TIO 18mg
QD+FORM 12mg BID
R, OL, MC,
3-way
xvr/6wk
(2wk 3)
Addition of morning FORM resulted
in improved FEV1, FVC, and IC
versus TIO alone. Addition of
evening FORM resulted in further
FEV1 improvement for 412 h but
FVC and IC increases lasted o12 h.
Addition of morning and morning-
evening FORM produced
corresponding decreases in rescue
medication use versus TIO alone
W.E. Berger, J.A. Nadel182
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Table 3 (continued )
Author N Mean age
(yr)
Study drugs Study design/
duration
Key findings
Van Noord et al.,31 71 64.9 FORM 12 mg BID; TIO
18mg QD; FORM 12 mg
QD+TIO 18mg QD
R, DB, DD,
MC, 3-way
xvr/18wk
(6wk 3)
Average FEV1 increase 0–24 h with
FORM/TIO superior to FORM or TIO
alone (both Po0.0001). FORM
versus TIO (NS). Results similar for
FVC, excepting TIO superiority to
FORM alone (Po0.05). Reduced use
of rescue medication with
combination versus FORM or TIO
alone (Po0.01) TIO versus FORM
(NS)
Yildiz et al.,36 60 68 IPRA 40 mg QID+THEO
200mg BID; FORM
12mg BID +THEO
200mg BID; IPRA
40mg QID +FORM
12mg BID
R, PG/12wk All study regimens produced similar
increases in FEV1, FVC, health
status measures (SGRQ)
ALB ¼ albuterol; AUC ¼ area under the curve; BUD ¼ budesonide; DB ¼ double-blind; DD ¼ double dummy; FEV1 ¼ forced expiratory
volume at 1 s; FORM ¼ formoterol; FLU ¼ fluticasone; FVC ¼ forced vital capacity; hs ¼ at bedtime; IC ¼ inspiratory capacity;
IPRA ¼ ipratropium; MC ¼ multicenter; MKT ¼ montelukast; P ¼ placebo; PEF ¼ peak expiratory flow; PG ¼ parallel group;
QID ¼ four times daily; R ¼ randomized; SB ¼ single-blind; SGRQ ¼ St. Georges Respiratory Questionnaire; TIO ¼ tiotropium;
xvr ¼ crossover.
aGroup mean not provided; range of means over treatment groups was 63–65 yr.
bPopulation with nonreversible disease defined as o12% or absolute 200mL following 400mg salbutamol.
cMedian value.
Efficacy and safety of formoterol for COPD 183monotherapy with either agent (all Po0.01). One unex-
pected finding was that FEV1 and FVC improvements at
30min post-treatment were greater with the combination of
a formoterol (LABA) and tiotropium (long-acting anti-
cholinergic) than with formoterol alone or tiotropium alone
(Po0.01). The authors concluded that although the time
course of effects for tiotropium and formoterol differed
significantly during acute exacerbations of COPD than in
stable COPD, the actions of formoterol and tiotropium were
complementary with respect to improvements in the ability
to manage acute exacerbations of COPD.Formoterol plus short-acting bronchodilators
In a crossover trial, D’Urzo and coworkers32 compared
formoterol 12 mg BID plus ipratropium 40 mg QID with
albuterol 200 mg QID plus ipratropium 40 mg QID over a
6-week period. Both regimens were effective in terms of
improvements in the primary efficacy variable, mean
morning PEF, but formoterol/ipratropium was superior to
albuterol/ipratropium (P ¼ 0.0003). Predose FEV1 increased
with formoterol/ipratropium, but decreased with albuterol/
ipratropium (Po0.0001). FEV1 levels were also greater with
formoterol/ipratropium at all post-treatment time points
through 6 h. Although peak FEV1 levels were reached more
slowly with formoterol/ipratropium than with albuterol/
ipratropium (2 versus 1 h, respectively), the peak levels and
FEV1 AUCs were greater with formoterol/ipratropium than
with albuterol/ipratropium (both Po0.0001). The propor-tions of patients without COPD exacerbations and propor-
tions with ‘‘bad days’’ were similar between the two
treatment groups.
More recently, the results of a 3-month study examining
the effects of combination bronchodilator therapy on
quality of life, assessed using the SGRQ, for patients with
COPD were reported by Yildiz and coworkers.36 Treatment
consisted of formoterol 12 mg BID plus oral theophylline
(200mg BID), ipratropium 40 mg QID plus theophylline, or
formoterol plus ipratropium. Overall scores improved
significantly in all treatment groups compared with base-
line. However, no significant differences were observed
between treatments. The formoterol/ipratropium combina-
tion was associated with significant improvement in FEV1
and FVC from baseline after 3 months. The differences
between groups were not statistically significant. Increases
in FEV1 correlated with improvements in health-related
quality of life. All three treatments resulted in a similar
proportion of patients reporting clinically significant im-
provements in total symptom scores (range: 66–68%).
Finally, Celik and colleagues35 examined the effect of
adding on montelukast, a leukotriene receptor antagonist,
to formoterol 12 mg BID plus ipratropium 40 mg BID treatment
regimen over a 2-month period in COPD patients with
nonreversible airway obstruction. The addition of montelu-
kast 10mg at bedtime resulted in significant improvements
in FEV1, FVC, and PEF levels compared with baseline levels
(Po0.05). Similarly, symptom, activity, impact, sensation of
dyspnea, and total SGRQ scores were improved in the
montelukast group (all Po0.05 versus baseline). The authors
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pium combination therapy results in additional benefits on
spirometric and quality-of-life measures.Effectiveness of formoterol in combination
with ICS in COPD treatment
The current COPD management guidelines recommend
addition of an ICS to bronchodilator therapy for patients
with an FEV1o50% predicted who experience repeated
exacerbations.1 Three trials have examined the effects of
adding formoterol to the ICS budesonide and reported
favorable results (Table 3).38–40
In a crossover study among 16 patients with moderate to
severe COPD on regular LABA therapy, Cazzola and collea-
gues38 compared the effects of single doses of formoterol
12 mg plus budesonide 400 mg with those of salmeterol 50 mg
plus fluticasone 250 mg over 12 h. FEV1 levels improved to a
similar extent with both regimens, as assessed by AUC0–12 h
levels (both Po0.001 versus baseline). Treatment with
formoterol/budesonide resulted in faster onset of action
and superior improvements in FEV1 levels compared with
salmeterol/fluticasone at both 2 and 6 h post-treatment
(Po0.05).
Two placebo-controlled studies compared treatment with
formoterol 9 mg plus budesonide 320 mg BID administered via
a single inhaler and treatment with formoterol 9 mg and
budesonide 200 or 400 mg BID administered alone.39,40 In a
12-month trial involving 812 patients with COPD, Szafranski
and coworkers39 demonstrated that treatment with combi-
nation therapy of formoterol and budesonide resulted in
increases in FEV1 that were similar to those achieved with
formoterol 4.5 mg BID alone (P ¼ NS) but significantly great-
er than those with budesonide 200 mg BID alone (Po0.001).
However, morning and evening PEF rates were greater with
combination therapy than with either agent alone (both
Po0.001). Combination treatment also resulted in fewer
mild exacerbations versus budesonide alone (P ¼ 0.022) and
fewer severe exacerbations versus formoterol alone
(P ¼ 0.403).
A related trial by Calverley and associates40 showed that
the combination of formoterol and budesonide provided
effective maintenance therapy over 12 months (Table 3).
Fewer patients receiving combination therapy withdrew
from the study because of worsening of COPD than those
receiving formoterol or budesonide monotherapy (Pp0.038).
Combination treatment also prolonged the time to first
COPD exacerbation (Po0.05 versus monotherapy with
formoterol and budesonide) and reduced the risk for
exacerbation by 23%, 30% and 29% relative to treatment
with formoterol, budesonide, and placebo, respectively.
Improvements in FEV1 following a steroid optimization
regimen during run-in were consistently maintained
throughout the study in the combination therapy group,
whereas these gains diminished throughout the study in the
other treatment groups (all Po0.002). Moreover, combina-
tion treatment resulted in significant improvements in the
SGRQ total scores and use of rescue medications compared
with all other treatments (Po0.05) and in total symptom
scores compared with placebo (Po0.001).Safety of formoterol in the treatment of COPD
Many of the adverse events (AEs) associated with
b2-adrenergic receptor agonists are pharmacologically pre-
dictable (ie, related to a- and b-adrenergic receptor
stimulation).41 Treatment with SABAs or LABAs can result
in tachycardia, arrhythmia, other cardiac AEs (e.g. ische-
mia, heart failure, cardiomyopathy), tremor, and metabolic
imbalances, such as decreased serum potassium levels or
increased glucose levels. However, these events are gen-
erally less pronounced with LABAs than with SABAs.9–11,42 It
should be noted that a recent large-scale, placebo-con-
trolled, observational study of salmeterol in 26,355 patients
with asthma was terminated prematurely because of a small
but statistically significant increase in respiratory-related
deaths that occurred primarily in African-American pa-
tients.43 This has resulted in a ‘‘black-box warning’’ in the
prescribing information for both salmeterol and formoterol
regarding the potential increased risk for asthma-related
deaths.6,44 Furthermore, the prescribing information for
both formoterol and salmeterol indicate that the use of
SABAs on a regular basis should be discontinued in patients
with asthma when initiating treatment with LABAs, and that
SABAs should only be used on an as-needed basis in these
patients because of possible cross tolerance. However, no
studies have been conducted to date that evaluated the
association of deaths with the use of LABAs in patients with
COPD. The current guidelines for COPD do not suggest any
restriction on the use of SABAs and LABAs in patients with
COPD.1
Formoterol has been well tolerated in placebo-controlled
trials, demonstrating a safety profile similar to placebo.26–28
Aalbers and colleagues26 reported that deterioration of
COPD and respiratory infection were the most frequent AEs
observed in all treatment groups in a 3-month dose-ranging
trial of formoterol 4.5, 9 or 18 mg BID. The incidence, type,
and severity of serious AEs in the 3 formoterol groups were
similar between groups treated with formoterol. Further-
more, there was no significant difference in patient with-
drawals (16–19%) across the four groups.
A second 3-month (n ¼ 780) placebo-controlled study
conducted by Dahl and coworkers27 compared treatment
with formoterol 12 and 24 mg BID, ipratropium 40 mg QID, and
placebo. Viral infections, COPD exacerbations, headache,
upper respiratory infection (URI), pharyngitis, chest pain,
coughing, and dyspnea were the most frequently reported
AEs. The AE rates were comparable among all groups. AEs
were considered drug related in 11%, 19%, 12%, and 12% of
patients in the formoterol 12 mg BID, formoterol 24 mg BID,
ipratropium, and placebo groups, respectively. The most
common drug-related AEs were headache, tremor, dry
mouth, muscle cramps, coughing, COPD exacerbations,
dyspnea, and pruritus. Heart rate and rhythm disorders
were rare in all groups. Cardiovascular AEs occurred in 13
patients, but involved only 1 and 2 patients treated with
formoterol 12 and 24 mg, respectively.
In a large (n ¼ 854) 12-month, placebo-controlled study
conducted by Rossi and colleagues,28 the incidence of AEs
among patients receiving formoterol 12 or 24 mg BID,
theophylline (individualized doses), or placebo was similar
across all groups. The most frequent events included viral
infection, COPD exacerbation, bronchitis, URI, dyspnea, and
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pain, nausea, vomiting) were reported more frequently in
theophylline-treated patients than by other groups. A
greater percentage of theophylline-treated patients also
experienced drug-related AEs (32%), compared with for-
moterol 12 mg BID (9%), 24 mg BID (8%), and placebo groups
(8%). Patients receiving theophylline were 2 or 4 times more
likely to discontinue treatment because of AEs than patients
taking placebo or formoterol, respectively. The incidence of
serious cardiac AEs among the groups was similar: 2%
formoterol 12 mg, 0% formoterol 24 mg, 2% theophylline,
and 1% placebo.
In studies reporting on the safety of salmeterol, heart
rates were increased by 2–5 beats per min with doses of
salmeterol up to 100 mg compared with placebo. Salmeterol
100 mg has been associated with a higher-than-normal rate
of premature ventricular beats and palpitations.45 Salme-
terol also appears to affect the QTc interval to a greater
extent than albuterol.41 However, high-dose (90mg) for-
moterol has minimal effect on heart rate and serum
potassium compared with terbutaline 10 mg.46 Although
tremor associated with salmeterol is dose related, the
incidence is less than that with albuterol.45,47,48 Salmeterol
is also associated with dose-related decreases in serum
potassium levels.49 Similar decreases have been seen with
formoterol. However, decreases with formoterol have
occurred only at very high doses and have not been
considered clinically significant.50
Small increases in airway hyperresponsiveness (AHR) have
been associated with regular or frequent use of SABAs.41
Formoterol and salmeterol have not been shown to increase
AHR in adults following challenge with specific or nonspecific
stimuli.41 Furthermore, neither drug has been associated
with rebound AHR, although tolerance to the bronchopro-
tective effects of both has been shown.41,51,52 However,
salmeterol has been associated with AHR and deterioration
of lung function in children.41,53 Results of a 6-month safety
and efficacy comparison of formoterol and salmeterol
conducted by Vervloet and coworkers30 indicated that both
drugs were well tolerated and that AEs were reported by
similar proportions of patients in both treatment groups. As
in other studies, viral infection, exacerbation of obstructive
airway disease, headache, rhinitis, and chest infection were
the most common AEs. Headache was the most frequently
reported drug-related AE. The incidences of AEs considered
to be drug-related were similar between groups.30
Adverse-event profiles reported in studies of formoterol
used in combination therapy regimens were similar to those
in placebo-controlled trials.26–28 In the 3-month study
comparing combination therapy of formoterol/ipratropium
with albuterol/ipratropium, D’Urzo and coworkers32 found
that dyspnea, COPD exacerbation, and pharyngitis were the
most frequently reported AEs in both groups during the
study. The AEs occurred more frequently in patients treated
with the albuterol/ipratropium combination than with
formoterol/ipratropium combination. Albuterol/ipratro-
pium was also associated with a higher proportion of severe
AEs. Moreover, a larger proportion of drug-related AEs were
reported with albuterol/ipratropium than with formoterol/
ipratropium. The most commonly reported drug-related AEs
were hypertension, dry mouth, and leg cramps in patients
taking formoterol/ipratropium and pharyngitis, dyspnea,dizziness, tremor, leg cramps, coughing, and exacerbation
of obstructive airway disease in the albuterol/ipratropium
group.
In two 12-month studies that compared monotherapy with
formoterol, or budesonide, or placebo with combination
therapy of formoterol/budesonide, AEs with combination
therapy were similar to those reported with monotherapy
with each component or with placebo.39,40 Frequencies of
event-related study withdrawals were similar among all
groups in one study by Szafranski and coworkers,39 and
slightly lower in the placebo group in the second trial
conducted by Calverley and colleagues.40
In a 3-week crossover comparison of formoterol 12 mg BID,
tiotropium 18 mg QD, and combination therapy with both
drugs, van Noord and coworkers31 found that all regimens
were well tolerated and that there were no relevant
between-treatment differences in AE rates. Nasopharyngi-
tis, headache, and exacerbations of COPD and dyspnea were
the most commonly reported events.
Few AEs were reported in noncontrolled, single-dose, or
dose-response studies of formoterol. The AEs reported were
primarily either known class effects of b2-adrenergic
receptor agonists such as muscle cramps, tremor, and
palpitations, or were considered unrelated to formoterol
treatment.14,15,18 No clinically important changes in labora-
tory tests, heart rate, or electrocardiography measurements
(including QTc), were associated with the use of formoterol,
regardless of dose or treatment duration.14,18–20,30,31,39,54–61Discussion
Bronchodilators are the mainstay of pharmacologic manage-
ment for patients with moderate to severe COPD.1 Among
agents approved for the treatment of COPD in the United
States, the LABA formoterol is characterized by rapid onset
and long duration of action. Inhalational therapy with
formoterol can produce a significant bronchodilatory effect
within 5min and maximal FEV1 increase within
30–60min.18,25 In placebo-controlled trials, formoterol
significantly improved lung function and maintained bene-
ficial bronchodilatory effects for up to 12 months.26–28
Formoterol also significantly reduced daytime and nighttime
symptoms of COPD, use of rescue medication, acute
exacerbations of COPD, and exacerbation-related hospitali-
zations.26–28
The efficacy of formoterol 12 mg BID is comparable to
salmeterol 50 mg BID and superior to ipratropium 40 mg QID in
improving lung function, controlling COPD symptoms, and
reducing the need for rescue medications.27,30 The bronch-
odilatory effect of twice-daily formoterol was similar to that
of once-daily tiotropium over a 24-h dosing period.31
Compared with theophylline, formoterol was more effective
in improving lung function, reducing exacerbations of COPD
of any severity, and increasing the number of days in which
rescue medication was unnecessary. Formoterol was also
better tolerated and associated with fewer AEs than
theophylline.28
Formoterol also improves lung function and symptom
control when administered in combination with other
bronchodilators. Albuterol/ipratropium combination ther-
apy resulted in improvements in FEV1, a more rapid
ARTICLE IN PRESS
W.E. Berger, J.A. Nadel186attainment of peak effect, and a reduction in the frequency
of COPD exacerbations than combination therapy with
formoterol/ipratropium.32 Similarly, combination therapy
with formoterol and budesonide resulted in improvements in
total symptom scores, longer time to first exacerbation, and
reduction in the number of exacerbations and use of rescue
medications compared with formoterol or budesonide
alone.39,40 The decrease in airway obstruction reported
with combined formoterol/budesonide treatment was com-
parable to that seen with the salmeterol/fluticasone
propionate combination.38
Formoterol is also effective when used as a rescue
medication for acute exacerbations of COPD in patients
already using an inhaled LABA (including formoterol) as
maintenance therapy for COPD. Additional doses of for-
moterol can be used safely to control symptoms. Onset of
effect with formoterol is similar to that with albuterol, but
has a significantly longer duration.54–57,59
In clinical trials, formoterol was better tolerated than
theophylline and at least as well-tolerated as budesonide,
salmeterol, albuterol, ipratropium, and tiotropium, regard-
less of administration as monotherapy or combination
therapy.26–28,30–32,39,40
Conclusions
Formoterol is a LABA that is effective and well tolerated in
management of COPD. Unlike other LABAs, formoterol offers
the benefit of rapid onset of action. Formoterol is effective
as monotherapy and in combination with other bronchodi-
lators or ICSs. The current guidelines for the management of
COPD recommend the use of inhaled long-acting broncho-
dilators as maintenance therapy in patients with moderate
to severe COPD. The rapid onset and prolonged duration of
action of formoterol makes it an ideal therapeutic option for
patients with this moderate to severe COPD.
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